Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital

Capone, Stephen; Abramyan, Shogik; Ross, Brent; Rosenberg, Jack M.; Zeibeq, John; Vasudevan, Viswanath; Samad, Reza; Gerolemou, Louis; Pinelis, Evgeny; Gasperino, James; Orsini, Jose

doi:10.7759/cureus.9809

Cited by 23 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We initially identified 5,000 articles based on our search criteria, most of which were irrelevant to our research objective or without published results ( Figure 1 ). Finally, we included 136 articles in our meta-analysis, which involved a total of 102,345 subjects ( Alam et al, 2020 ; Almazeedi et al, 2020 ; Asai et al, 2020 ; Bakhshaliyev et al, 2020 ; Beigel et al, 2020 ; Berenguer et al, 2020 ; Bhandari et al, 2020 ; Bhatraju et al, 2020 ; Boulware et al, 2020 ; Buckner et al, 2020 ; Cai et al, 2020 ; Campochiaro et al, 2020 ; Cao et al, 2020a ; Cao et al, 2020b ; Capone et al, 2020 ; Casas-Rojo et al, 2020 ; Catteau et al, 2020 ; Chen et al, 2020a ; Chen et al, 2020b ; Chen et al, 2020c ; Chen et al, 2020d ; Chen Jun et al, 2020 ; Colaneri et al, 2020 ; Deng et al, 2020 ; Dequin et al, 2020 ; Di Lorenzo et al, 2020 ; Fauvel et al, 2020 ; Ferrando et al, 2020 ; Fried et al, 2020 ; García−Salido et al, 2020 ; Gautret et al, 2020 ; Geleris et al, 2020 ; Grein et al, 2020 ; Guervilly et al, 2020 ; Gupta et al, 2020 ; Han et al, 2020 ; Heffler et al, 2020 ; Hong et al, 2020 ; Hu et al, 2020a ; Hu et al, 2020b ; Huang et al, 2020a ; Huang et al, 2020b ; Huang et al, 2020c ; Hung et al, 2020 ; Hur et al, 2020 ; Jacobs et al, 2020 ; Jiang et al, 2020 ; Karolyi et al, 2020 ; Kaushik et al, 2020 ; Khamis et al, 2020 ; Kim et al, 2020a ; Kim et al, 2020b ; Koleilat et al, 2020 ; Krishnan et al, 2020 ; ...…”

Section: Resultsmentioning

confidence: 99%

Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background: Limited data on the efficacy and safety of currently applied COVID-19 therapeutics and their impact on COVID-19 outcomes have raised additional concern.Objective and Methods: To estimate the efficacy and safety of COVID-19 therapeutics, we performed meta-analyses of the studies reporting clinical features and treatments of COVID-19 published from January 21 to September 6, 2020.Results: We included 136 studies that involved 102,345 COVID-19 patients. The most prevalent treatments were antibiotics (proportion: 0.59, 95% CI: [0.51, 0.67]) and antivirals (proportion: 0.52, 95% CI: [0.44, 0.60]). The combination of lopinavir/ritonavir and Arbidol was the most effective in treating COVID-19 (standardized mean difference (SMD) = 0.68, 95% CI: [0.15, 1.21]). The use of corticosteroids was associated with a small clinical improvement (SMD = −0.40, 95% CI: [−0.85, −0.23]), but with a higher risk of disease progression and death (mortality: RR = 9.26, 95% CI: [4.81, 17.80]; hospitalization length: RR = 1.54, 95% CI: [1.39, 1.72]; severe adverse events: RR = 2.65, 95% CI: [2.09, 3.37]). The use of hydroxychloroquine was associated with a higher risk of death (RR = 1.68, 95% CI: [1.18, 2.38]). The combination of lopinavir/ritonavir, ribavirin, and interferon-β (RR = 0.34, 95% CI: [0.22, 0.54]); hydroxychloroquine (RR = 0.58, 95% CI: [0.39, 0.58]); and lopinavir/ritonavir (RR = 0.72, 95% CI: [0.56, 0.91]) was associated with reduced hospitalization length. Hydrocortisone (RR = 0.05, 95% CI: [0.03, 0.10]) and remdesivir (RR = 0.74, 95% CI: [0.62, 0.90]) were associated with lower incidence of severe adverse events. Dexamethasone was not significant in reducing disease progression (RR = 0.45, 95% CI: [0.16, 1.25]) and mortality (RR = 0.90, 95% CI: [0.70, 1.16]). The estimated combination of corticosteroids with antivirals was associated with a better clinical improvement than antivirals alone (SMD = −1.09, 95% CI: [−1.64, −0.53]).Conclusion: Antivirals are safe and effective in COVID-19 treatment. Remdesivir cannot significantly reduce COVID-19 mortality and hospitalization length, while it is associated with a lower incidence of severe adverse events. Corticosteroids could increase COVID-19 severity, but it could be beneficial when combined with antivirals. Our data are potentially valuable for the clinical treatment and management of COVID-19 patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Selected data on obesity and outcome are shown in Table 1. [17][18][19][20][21][22][23] In western countries, although data from Italy have confirmed earlier Chinese reports, 24 a French study showed that patients with BMI > 35 kg/m 2 were at significantly higher risk for the requirement of intensive mechanical ventilation compared to normal-weight individuals (with BMI lower than 25 kg/m 2 ), even after adjusting for age, diabetes and hypertension. 25 These results were later replicated in a different hospital in France 26 and have generated more interest in the association between adipose tissue excess and disease pathophysiology.…”

Section: Epidemiological Datamentioning

confidence: 77%

Obesity and COVID‐19: A jigsaw puzzle with still missing pieces

Michalakis¹,

Panagiotou

Ilias

et al. 2020

Clinical Obesity

View full text Add to dashboard Cite

SummaryApart from posing various mechanical and medical issues compromising general health, obesity is a major factor for respiratory tract infections, due to specific inflammation and immunological compromise. The burden of obesity on morbidity and mortality of SARS‐CoV‐2 infection/COVID‐19 is considerable. Herein, we aimed to search the literature and present to the readers pathophysiologic pathways that may associate obesity and COVID‐19. We present potential mechanisms, which might partly explain why patients with obesity are more prone to suffer from respiratory infections in the context of COVID‐19. Better understanding of these pathways could eventually guide management strategies and therapies for COVID‐19 in the future.

show abstract

“…Subsequently, 44 articles were excluded because of a sample size less than 100, 47 articles were eliminated due to the potential duplicate patients, and two articles were removed because they reported unclear prevalence of asthma in COVID-19 patients (eTable 2). Ultimately, 116 articles (119 studies) 4 , 6 , 7 , 8 , 9 , 10 , 11 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 ,…”

Section: Resultsmentioning

confidence: 99%

Asthma in patients with coronavirus disease 2019

Shi

Xiao

et al. 2021

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Background It is unclear if there is the influence of asthma on contracting COVID-19, or having worse outcomes from COVID-19 disease. Objective To explore the prevalence of asthma in COVID-19 patients and the relationship between asthma and COVID-19 patients with poor outcomes. Methods The pooled prevalence of asthma in COVID-19 patients and corresponding 95% confidence interval (CI) were estimated. The pooled effect size (ES) was used to evaluate the association between asthma and COVID-19 patients with poor outcomes. Results The pooled prevalence of asthma in COVID-19 patients worldwide was 8.3% (95% CI 7.6-9.0%) based on 116 articles (119 studies) with 403,392 cases. The pooled ES based on unadjusted effect estimates showed that asthma was not associated with the reduced risk of poor outcomes in COVID-19 patients (ES 0.91, 95% CI 0.78-1.06). Similarly, the pooled ES based on unadjusted effect estimates revealed that asthma was not associated with the reduced risk of mortality in COVID19 patients (ES 0.88, 95% CI 0.73-1.05). However, the pooled ES based on adjusted effect estimates indicated that asthma was significantly associated with the reduced risk of mortality in COVID-19 patients (ES 0.80, 95% CI 0.74-0.86). Conclusion The pooled prevalence of asthma in COVID-19 patients was similar to that in the general population, and asthma might be an independent protective factor for the death of COVID-19 patients, which suggests that we should pay high attention to COVID-19 patients with asthma and take locally tailored interventions and treatment. Further well-designed studies with large sample sizes are required to verify our findings.

show abstract

Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital

Cited by 23 publications

References 18 publications

Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis

Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis

Obesity and COVID‐19: A jigsaw puzzle with still missing pieces

Asthma in patients with coronavirus disease 2019

Contact Info

Product

Resources

About